Intravenous colistin combination is superior to monotherapy against carbapenem-resistant gram-negative bacterial infections: evidence from seven randomized controlled trials

Zhong-dong Li (zhdl009@126.com)  
Beijing Electric Power Hospital

Genzhu Wang  
Beijing Electric Power Hospital  
https://orcid.org/0000-0002-3164-6424

Zhikun Xun  
Beijing Electric Power Hospital

Xiaoying Wang  
Beijing Electric Power Hospital

Qiang Sun  
Beijing Electric Power Hospital

Baiqian Xing  
Beijing Electric Power Hospital

Research article

Keywords: Colistin, Monotherapy, Combination therapy, Carbapenem-resistant bacteria

Posted Date: November 4th, 2019

DOI: https://doi.org/10.21203/rs.2.16821/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background Previous meta-analysis based on five randomized controlled trials (RCTs) did not display that intravenous colistin-based combination therapy is more efficacious than monotherapy against carbapenem resistant gram-negative bacterial infections. This meta-analysis aimed to further elucidate the efficacy.

Methods PubMed, Embase, and Cochrane databases were searched up to March 2019 and only RCTs evaluating the combination therapy versus monotherapy against carbapenem or even colistin-resistant gram-negative bacteria infections were included. RevMan 5.3 was used to perform meta-analysis.

Results Seven RCTs involving 859 patients were included. Total analysis showed that the combination therapy had a trend towards higher microbial response (RR, 1.21; 95% CI, 0.98 –1.51), lower infection-related mortality (RR, 0.75; 95% CI, 0.53–1.05), and significantly lower nephrotoxicity (RR, 0.77; 95% CI, 0.60 – 0.98) than monotherapy. Subgroup analysis on carbapenem-resistant A. baumannii infections displayed that the combination therapy had significantly higher microbiological response (RR, 1.39; P <0.001; 95% CI, 1.19–1.61). Another subgroup analysis on combination regimen for colistin plus rifampicin showed that the combination therapy had significantly higher eradication rate to carbapenem - resistant A. baumannii (RR, 1.35; 95% CI, 1.08–1.68). However, total and subgroup analysis showed no significant difference in all-cause mortality.

Conclusions The present study suggests that intravenous colistin-based combination regimen, especially colistin plus rifampicin, may be superior to colistin alone against gram-negative bacterial infections, especially A. baumannii infection

Background

With the current emergence of carbapenem-resistant gram-negative bacteria including Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae worldwide [1–3] and the severe shortage of new active antimicrobial agents, intravenous polymyxins including colistin and polymyxin B which were abandoned due to high incidence of nephrotoxicity in the early 1970s [4], are now reconsidered as an effective treatment [5–9]. However, polymyxins-resistant gram-negative bacteria, which are also resistant to carbapenem, have occasionally emerged [3, 10]. These carbapenem-resistant gram-negative bacteria have not only posed an urgent threat to global public health, but also become an immense challenge for clinical therapy [11–14].

To solve the above therapeutic problems, some respective or retrospective studies compared the effectiveness and nephrotoxicity of intravenous colistin-based combination therapy and high dose colistin monotherapy [15–17]. However, these clinical studies did not show consistent results on the effectiveness. To resolve these inconsistent findings, four meta-analyses were performed by Zusman et al. in 2017 [18], Vardakas et al. in 2018 [19], Wang et al. in 2018 [20] and Cheng et al. in 2018 [21], respectively. But only the meta-analysis conducted by Cheng et al. [21] provided higher quality evidence based on five prospective randomized controlled trials (RCTs [22–26]) to find that intravenous colistin-based combination therapy was not superior to monotherapy. Recently, two additional RCTs [27, 28] compared the effects of intravenous colistin combination therapy and monotherapy on carbapenem- and colistin-resistant gram-negative bacteria infections. Therefore, the present meta-analysis was conducted based on seven RCTs further to provide higher quality evidence to elucidate whether intravenous colistin combination therapy is better than monotherapy against carbapenem-resistant gram-negative bacterial infections.

Methods

This meta-analysis was performed in accordance with the PRISMA-P (preferred reporting items for systematic reviews and meta-analysis protocols) statement which is recommended for the establishment of a systematic review and meta-
Focused question

Is intravenous colistin-based Combination therapy more efficacious than monotherapy in the treatment of carbapenem-resistant gram-negative bacteria infections?

Inclusion and exclusion criteria

Publications that were not restricted by language were included. The inclusion criteria in the present meta-analysis were as follows: (1) RCTs; (2) the clinical effectiveness and nephrotoxicity of colistin-based combination antimicrobial therapy and colistin monotherapy were compared in the treatment of carbapenem- and colistin- gram-negative bacteria infections in adult patients; (3) colistin or polymyxin B was administered intravenously. Studies were excluded if they did not meet each of these inclusion criteria.

Search strategies

All clinical studies were identified by a systematic review of the literature from the PubMed, Embase, and Cochrane databases up to March 2019 using the following search terms: "colistin or polymyxin," "gram negative bacteria or Acinetobacter baumannii or Enterobacteriaceae or Klebsiella pneumoniae or Pseudomonas aeruginosa," and "prospective or randomized." In addition, the reference lists of the selected manuscripts and related reviews were also screened manually to determine whether additional publications were available. The search strategies used are shown as follow.

1) PubMed

("colistin" [MeSH Terms] OR "colistin" [All Fields]) OR ("polymyxins" [MeSH Terms] OR "polymyxins" [All Fields] OR "polymyxin" [All Fields]) AND ("gram negative bacteria" [All Fields] OR "gram-negative bacteria" [MeSH Terms] OR ("gram-negative" [All Fields] AND "bacteria" [All Fields]) OR "gram-negative bacteria" [All Fields] OR ("gram" [All Fields] AND "negative" [All Fields] AND "bacteria" [All Fields])) OR "gram negative bacteria" [All Fields]) OR ("Acinetobacter baumannii" [MeSH Terms] OR ("Acinetobacter" [All Fields] AND "baumannii" [All Fields]) OR "Acinetobacter baumannii" [All Fields]) OR ("Klebsiella pneumoniae" [MeSH Terms] OR ("Klebsiella" [All Fields] AND "pneumoniae" [All Fields]) OR "Klebsiella pneumoniae" [All Fields]) OR ("Pseudomonas aeruginosa" [MeSH Terms] OR ("Pseudomonas" [All Fields] AND "aeruginosa" [All Fields]) OR "Pseudomonas aeruginosa" [All Fields]) OR ("Enterobacteriaceae" [MeSH Terms] OR "Enterobacteriaceae" [All Fields]) AND ("longitudinal studies" [MeSH Terms] OR ("longitudinal" [All Fields] AND "studies" [All Fields]) OR "longitudinal studies" [All Fields] OR "prospective" [All Fields]) OR ("random allocation" [MeSH Terms] OR ("random" [All Fields] AND "allocation" [All Fields]) OR "random allocation" [All Fields] OR "randomized" [All Fields] OR randomized [All Fields]).

2) Embase.

(1) colistin OR polymyxin;

(2) gram negative bacteria OR Acinetobacter baumannii OR Klebsiella pneumonia OR Pseudomonas aeruginosa OR Enterobacteriaceae,

(3) randomized OR prospective;

(4) (1) AND (2) AND (3).

3) Cochrane databases.
(1) MeSH descriptor colistin explode all trees;
(2) MeSH descriptor polymyxin explode all trees;
(3) (1) OR (2).

Study selection and data extraction

During study selection, duplicate studies or datasets were firstly removed from the included titles using EndNote software. The titles and summaries of the rest of studies were then sifted through, followed by full-text screening according to the inclusion criteria described above (Figure 1). The results were independently screened by two authors, and a third author was consulted if any discrepancies occurred.

The following data, including the year of publication, the place of study, the type of infection, bacteria, the dosage of colistin including loading dose and combined antimicrobial regimens, microbiological outcomes, infection-related mortality, all-cause mortality and nephrotoxicity, were extracted from each included study.

Quality assessment

Cochrane risk of bias assessment tool was used to evaluate the quality of enrolled RCTs and the risk of bias [30]. The risks of bias include random sequence generation (selection bias), assignment concealment (selection bias), blinding of participants and personnel (performance bias), blind assessment of outcome (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other biases. These bias risks contained three levels: low, unclear and high (Figure 2).

Definitions and outcomes

The main outcome was microbial response or microbial eradication because this index can really reflect the effectiveness of antimicrobial drugs. Secondary outcomes included all-cause or crude mortality at any timeframe, which mainly referred to 28- or 30-day incidence, infection-related mortality, and nephrotoxicity. The mean/median colistin dose or the administered dose of more than 6 million international units (MIU) was defined as high dose of colistin, as mentioned earlier [21].

Statistical analysis

Review Manager Version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) was used to perform the statistical analysis. The between-study heterogeneity was evaluated by Q test and $I^2$, Where the $P$-value was less than 0.05 and $I^2$ was more than 50%, heterogeneity was defined as significant and the Mantel–Haenszel random effects model was used. Otherwise, the fixed-effects model was used.

The pooled risk ratio (RR) and 95% confidence interval (CI) were calculated for result analysis. Sensitivity analyses were performed by the sequential omission of each study.

Ethics

Ethical approval was not required for such types of research articles.

Results

Study selection and characteristics
A total of 7 RCTs that met the inclusion criteria were included in this meta-analysis (Figure 1). Six out of seven studies included were open label, and except one bias, the blinding of participants and personnel (performance bias), most of the biases were classified as low or unclear risk of bias (Figure 2 and Figure 3).

The total number of patients included was 859 and mean age of these patients ranged from 56.2 to 76.0 years according to mean age provided by 7 RCTs papers.

Pneumonia, including ventilator-associated pneumonia and hospital-acquired pneumonia, was primary Infection type, and bloodstream infection was the next (Table 1). Carbapenem-resistant *A. baumannii* presented in the studies by Aydemir et al. [22], Makirs et al. [25], and Sirijatuphat et al. [24], extensive-drug including carbapenem resistant *A. baumannii* in the study by Durante-Mangoni et al. [23], Colistin-resistant *A. baumannii* in the study by Park et al. [28], carbapenem-resistant *K. pneumoniae* in the study by Abdelsalam et al. [27], and carbapenem-resistant gram-negative bacteria, including *A. baumannii*, *Enterobacteriaceae*, *Pseudomonas*, and others, in the study by Paul et al. [26]. There are 25.0% patients who complicated chronic kidney diseases.

All included studies designed intravenous colistin monotherapy and colistin-based combination regimens, the latter of which included colistin plus rifampicin [22, 23, 28], fosfomycin [24], meropenem [26, 27], or ampicillin-sulbactam [25]. Five studies [22, 24–27] adopted a high dose of colistin, among which two studies [26, 27] used a loading dose of colistin, one study [23] used a low dose of colistin, and another study [28] did not report the dose of colistin.

Six studies [22–27] reported the outcome of microbial response, seven [22–28] reported the outcome of crude mortality, four [22–25] reported the outcome of infection-related mortality, and four [23, 24, 26, 28] reported the outcome of nephrotoxicity (Table 2).

Meta-analysis results

1) Microbiological response

Intravenous colistin-based combination therapy showed a trend towards significantly higher microbiological response (RR, 1.21; *P* = 0.08; 95% CI, 0.98–1.51; *I*² = 68%; Figure 4a). Subgroup analysis on carbapenem-resistant *A. baumannii* infections displayed that colistin-based combination therapy had significantly higher microbiological response (RR, 1.39; *P* < 0.001; 95% CI, 1.19–1.61; *I*² = 45%; Figure 4b). Subgroup analysis on combination regimen for colistin plus rifampicin also displayed that colistin-based combination therapy had significantly higher eradication rate to carbapenem-resistant *A. baumannii* infections (RR, 1.35; *P* = 0.008; 95% CI, 1.08–1.68; *I*² = 0%; Figure 4c).

2) All-cause mortality.

All-cause mortality was not significantly different between patients receiving intravenous colistin-based combination therapy and those receiving monotherapy (RR, 0.96; *P* = 0.57; 95% CI, 0.83–1.11; *I*² = 12%; Figure 5a). Sensitivity analysis showed similar findings by the sequential omission of each study. Subgroup analysis on carbapenem-resistant *A. baumannii* infections displayed that colistin-based combination therapy was also not associated with lower all-cause mortality than monotherapy (RR, 1.08; *P* = 0.58; 95% CI, 0.83–1.40; *I*² = 52%; Figure 5b). Subgroup analysis on combination regimen for colistin plus rifampicin displayed that colistin-based combination therapy was not associated with lower all-cause mortality than monotherapy (RR, 0.98; *P* = 0.86; 95% CI, 0.76–1.26; *I*² = 0%; Figure 5c).

3) Infection-related mortality

Four studies [22–25] (Table 2) reported the results of infection-related mortality, and intravenous colistin-based combination therapy showed a trend towards lower infection-related mortality (RR, 0.75; *P* = 0.09; 95% CI, 0.53–1.05; *I*² =
4) Nephrotoxicity

Intravenous colistin-based combination therapy resulted in significantly lower nephrotoxicity as compared with colistin monotherapy (RR, 0.77; \( P = 0.03; \) 95% CI, 0.60–0.98; \( I^2 = 0.0\% \); Figure 7).

**Discussion**

This meta-analysis included seven RCTs [22–28] involving 433 patients treated with intravenous colistin in combination with other antibiotics and 426 patients treated with intravenous colistin alone. There are some inconsistent outcomes among the 7 studies included, which may be related to variations in individual study characteristics, including patient population with different complications, study place, clinical setting, pathogen and sample sizes. Therefore, the present meta-analysis increases the likelihood of identifying true efficacy and nephrotoxicity of intravenous colistin-based combination strategy against carbapenem-resistant gram-negative infections.

Of the seven studies [22–28] included, six [22–27] reported microbiological response, i.e., microbial eradication. Our meta-analysis found that colistin-based combination therapy showed a trend towards higher microbial eradication than colistin monotherapy, which indicated that colistin-based combination therapy may be better than colistin monotherapy. Further analysis found that of these six studies included, five by Aydemir et al., [22]Durante-Mamgoni et al., [23] Makris et al., [25] Park et al. [28] and Sirijatuphat et al. [24] showed this trend. Our results confirmed the results found in most of these studies. Subgroup analysis found that colistin-based combination regimen, especially colistin plus rifampicin regimen, have significantly higher eradication rates to \( A. \text{baumannii} \), indicating this combination regimen have a greater advantage in the treatment of carbapenem-resistant \( A. \text{baumannii} \) infections than colistine alone.

Four studies [22–25] included in this meta-analysis were involved in infection-related mortality, pathogen of which was all \( A. \text{baumannii} \). Intravenous colistin-based combination therapy was found a trend towards lower mortality. This was because these studies [22–25] all showed this trend. This finding was consistent with the result of microbiological response index, further indicating that an intravenous colistin-based combination regimen may be superior to colistin alone in the treatment of carbapenem-resistant \( A. \text{baumannii} \) infection.

Overall analysis and subgroup analysis on combination regimen for colistin plus rifampicin and on carbapenem-resistant \( A. \text{baumannii} \) infections showed that all-cause or crude mortality was not significantly different between the patients receiving colistin-based combination therapy and the patients receiving intravenous colistin monotherapy, which was similar to the result reported by Cheng et al. [21]. Of the seven RCTs [22–28] included, only study by Abdelsalam et al. [27] demonstrated significantly higher all-cause mortality in patients treated with colistin monotherapy than in those treated with colistin-based combination therapy (RR, 2.60; 95%CI, 1.06–6.39), other studies [22–26, 28] showed no difference in all-cause mortality. Therefore, our meta-analysis did not obtain positive results, too. All-cause mortality was not only related to the severity of infection and time of administration, but was also correlated with other pathophysiological factors such as older age, higher Charlson score, congestive heart failure, chronic kidney disease, diabetes mellitus, a need for hemodynamic support, dialysis, higher Sequential Organ Failure Assessment (SOFA) score, and higher creatinine level [31]. Therefore, the index of all-cause mortality can not really reflect the efficacy of antibacterial drugs.

Four studies [23, 24, 26, 27] reported the risk of nephrotoxicity according to risk, injury, failure, loss, and end-stage renal disease (RIFLE) criteria. Our meta-analysis found that colistin-based combination therapy was associated with significantly lower nephrotoxicity than colistin monotherapy, which differed from the result reported by Cheng et al. [21]. This was because these four studies all showed this trend. Of these four studies, [23, 24, 26, 27] nephrotoxicity was
mainly correlated with the factor of infection besides colistin autonomous induction. The antibiotic combination regimen differed in these four RCTs, [23, 24, 26, 27] where rifampicin, fosfomycin, and meropenem were administered. Rifampicin, fosfomycin, and meropenem were not found to have protection against nephrotoxicity of colistin up to now. As mentioned above, our meta-analysis demonstrated that the combination therapy showed a trend towards lower infection-related mortality and significantly higher microbiological response. Therefore, we believe that lower nephrotoxicity in patients treated with combination regimens may be related to infection control.

**Novelty and limitations**

Our meta-analysis has some strengths. Besides an unrestricted search process, duplicate review procedures for the search, sensitivity analysis, and assessments of the risks of biases, only RCTs were included in the meta-analysis. Therefore, the risk of bias in the present meta-analysis should be greatly minimized, and the level of evidence was stronger. However, this meta-analysis also has several limitations. Firstly, although seven RCTs were included, six studies [22–27] were open label; thus, performance bias, the blinding of participants and personnel, may have been present. Secondly, as we know, interstudy heterogeneity and publication bias are major limitations correlated with meta-analyses. Heterogeneity can be caused by many factors such as patient population with different complication, sample sizes, clinical setting and antibacterial regimen. We found that there was obvious heterogeneity in analyzing microbiological response. This was due to larger sample sizes and different pathogen in the study by Paul et al. [26]. When the study by Paul et al. [26] was removed, $I^2$ value was significantly decreased and $P$ value was above 0.05 (data not shown). As for publication bias, we could not obtain observation due to not enough study numbers. Thirdly, although a wide search in three different databases was used to find studies for inclusion in the meta-analysis, it is impossible to confirm that all available studies comparing the efficacy and nephrotoxicity of intravenous colistin or polymyxin B-based combination therapy and colistin or polymyxin B monotherapy were included, presenting another main limitation of this meta-analysis.

**Conclusions**

Our meta-analysis found some encouraging results based on higher quality evidence. Combined intravenous therapy based on colistin showed a trend towards higher microbiological response, lower infection-related mortality and significantly lower nephrotoxicity than colistin monotherapy against carbapenem-resistant gram-negative bacterial infections, especially *A. baumannii* infection.

**Abbreviations**

RCT: randomized controlled trials; PRISMA-P: preferred reporting items for systematic reviews and meta-analysis protocols; MIU: million international units; RR: risk ratio; CI: confidence interval; RIFLE: risk, injury, failure, loss, and end-stage renal disease.

**Declarations**

**Funding**

There was no external funding for this research.

**Availability of data and materials**

All data and materials used in this research are freely available. References have been provided.
Authors’ contributions
ZDL designed the study, searched the literature, selected the study, analyzed and interpreted data, and drafted and revised the article. ZKK, XYW, QS and BQX participated in the literature search and study selection. GZW took part in assessments of quality. The authors declare that there are no competing interests regarding the publication of this paper.

Ethics approval and consent to participate
Ethical approval was not applicable for this systematic review and meta-analysis.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. World Health Organization (WHO). Antimicrobial resistance: global report on surveillance 2014. Available from: http://www.who.int/drugresistance/documents/surveillancereport/en/.

2. European Centre for Disease Prevention and Control (ECDC). The ECDC EARS-Net report 2013. Available from: http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillanceeurope–2013.pdf.

3. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.

4. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72(6):857–68.

5. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589–601.

6. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49(9):3624–30.

7. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22(6):535–43.

8. Roberts KD, Azad MA, Wang J, Home AS, Thompson PE, Nation RL, et al. Antimicrobial activity and toxicity of the major lipopeptide components of polymyxin B and colistin: last-line antibiotics against multidrug-resistant Gram-negative bacteria. ACS Infect Dis. 2015;1(11):568–75.

9. Velkov T, Roberts KD, Thompson PE, Li J. Polymyxins: a new hope in combating Gram-negative superbugs? Future Med Chem. 2016;8(10):1017–25.

10. Guducuoglu H, Gursoy NC, Yakupogullari Y, Parlak M, Karasin G, Sunnetcioglu M, et al. Hospital outbreak of a colistin-resistant, NDM–1- and OXA–48-producing Klebsiella pneumoniae: high mortality from pandrug resistance. Microb Drug Resist. 2018;24(7):966–72.
11. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20(7):1170–5.

12. Lemos EV, de la Hoz FP, Einarson TR, McGhan WF, Quevedo E, Castaneda C, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect. 2014;20(5):416–23.

13. Zhang Y, Chen XL, Huang AW, Liu SL, Liu WJ, Zhang N, et al. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg Microbes Infect. 2016;5:e27.

14. Tomczyk S, Zanichelli V, Grayson ML, Twyman A, Abbas M, Pires D, et al. Control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in healthcare facilities: a systematic review and reanalysis of quasi-experimental studies. Clin Infect Dis. 2019;68(5):873–84.

15. Viale P, Giannella M, Tedeschi S, Lewis R. Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians. Curr Opin Pharmacol. 2015;24:30–7.

16. Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2016;29(6):583–94.

17. Leuppi-Taegtmeyer AB, Decosterd L, Osthoff M, Mueller NJ, Buclin T, Corti N. Multicenter population pharmacokinetic study of colistimethate sodium and colistin dosed as in normal renal function in patients on continuous renal replacement therapy. Antimicrob Agents Chemother. 2019;63(2).

18. Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(1):29–39.

19. Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME. Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018;51(4):535–47.

20. Wang J, Niu H, Wang R, Cai Y. Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: A systematic review and meta-analysis. Int J Antimicrob Agents. 2019;53(4):383–400.

21. Cheng IL, Chen YH, Lai CC, Tang HJ. Intravenous colistin monotherapy versus combination therapy against carbapenem-resistant Gram-negative bacteria infections: meta-analysis of randomized controlled trials. J Clin Med. 2018;7(8).

22. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;141(6):1214–22.

23. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–58.

24. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58(9):5598–601.

25. Makris D, Petinati E, Tsolaki V, Manoulakas E, Mantzarlis K, Apostolopoulou O, et al. Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study. Indian J Crit Care Med. 2018;22(2):67–77.
26. Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400.

27. Abdelsalam MFA, Abdalla MS, El-Abhar HSE. Prospective, comparative clinical study between high-dose colistin monotherapy and colistin-meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist. 2018;15:127–35.

28. Park HJ, Cho JH, Kim HJ, Han SH, Jeong SH, Byun MK. Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial. J Glob Antimicrob Resist. 2019;17:66–71.

29. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.

30. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

31. Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, et al. Treatment outcomes of colistin- and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial. Clin Infect Dis. 2019;69(5):769–76.

Tables

Table 1. Characteristics of the included studies.
| Author/ Publication Year | Study Year | Country | Bacteria | Setting | Infection Type (%) | Usage of IV Colistin Dose | Combination regimen |
|-------------------------|------------|---------|----------|---------|---------------------|--------------------------|---------------------|
| Aydemir, 2013 22        | 2011-2012 | Turkey  | Carbapenem-resistant | ICU VAP (100) | 300 mg colistin based activity/ day, t.id. (9 MIU per day) | Colistin+ Rifampicin |
| Durante-Mangoni, 2013 23| 2010-2011 | Italy   | Extensive-drug resistant A. baumannii | ICU VAP (69), BSI (20), | 2 MIU every 8 h | Colistin+ Rifampicin |
| Sirijatuphat, 2014 24   | 2010-2011 | Thailand | Carbapenem-resistant A. baumannii | ICU and ward BSI (5.4), UTI (5.4), IAI (6.4), SSSI (3.2), CNSI (1.0), other (2.1) | 5 mg colistin based activity /kg/ day (9 MIU per day) | Colistin+ Fosfomycin |
| Paul, 2018 26           | 2013-2016 | Israel, Greece, Italy | Carbapenem-resistant gram-negative bacteria, including A. baumannii, Enterobacteriaceae, Pseudomonas, and others | ICU and ward VAP/HAP (44.8), BSI (42.6), UTI (6.4), pVAP (6.2) | 9 MIU loading, followed by 4.5 MIU every 12 h | Colistin+ Meropenem |
| Makirs, 2018 25         | -         | Greece  | Carbapenem-resistant A. baumannii | ICU VAP (100) | 3 MIU t.i.d. | Colistin+ Ampicillin-sulbactam |
| Park, 2018 28           | 2016-2018 | Korea   | Colistin-resistant A. baumannii | Ward VAP (100) | No reported. | Colistin+ Rifampicin |
| Abdelsalam, 2018 27     | 2016-2016 | Egypt   | Carbapenem-resistant K. pneumoniae A. baumannii | ICU HAP (100) with UTI (16.6) | 9 MIU loading, followed by 3 MIU every 8 h (CLCr>50 mL/min), 4.5 MIU every 24 h (CLCr 20 – 50 mL/min). | Colistin+ Meropenem |
|                        |            |         |          |         |                    |                          |                     |

Page 11/17
ICU, intensive care unit; VAP, ventilator-associated pneumonia; BSI, bloodstream infection; HAP, hospital-acquired pneumonia; cIAI, complicated intra-abdominal infection; UTI, urinary tract infection; SSTI, skin and soft tissue infection; CNSI, central nervous system infection; MIU, million international units; IV, intravenous; t.i.d, three times per day.

Table 2. Outcomes of combination therapy versus monotherapy

| Author and publication year | Microbial response | Crude mortality | Infection-related death | Nephrotoxicity |
|-----------------------------|-------------------|-----------------|-------------------------|----------------|
|                             | Combination       | Monotherapy     | Combination            | Monotherapy    | Combination | Monotherapy |
| Aydemir, 2013 22            | 15/21*            | 13/22           | 13/21                   | 16/22          | 8/21        | 14/22        | NR          | NR          |
| Durante-Mangoni, 2013 23    | 63/104            | 47/105          | 45/104                  | 45/105         | 22/104      | 28/105       | 24/101      | 29/101      |
| Sirijatuphat, 2014 24       | 47/47             | 38/47           | 22/47                   | 27/47          | 10/47       | 13/47        | 25/47       | 28/47       |
| Paul, 2018 26               | 135/208           | 136/198         | 94/208                  | 86/198         | NR          | NR           | 18/88       | 27/77       |
| Makirs, 2018 25             | 10/20             | 1/19            | 7/20                    | 4/19           | 2/20        | 2/19         | NR          | NR          |
| Park, 2018 28               | 3/3               | 2/5             | 1/3                     | 1/5            | NR          | NR           | NR          | NR          |
| Abdelsalam, 2018 27         | NR                | NR              | 5/30                    | 13/30          | NR          | NR           | 6/30        | 8/30        |

*: number of events / total number.  NR, the outcome was not reported.
Figure 1

Flow diagram of the study selection process.

Figure 2

| Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias |
|--------------------------------------------|----------------------------------------|----------------------------------------------------------|-----------------------------------------------|----------------------------------------|----------------------------------------|-----------|
| ![Bar Chart](chart.png)                     | ![Bar Chart](chart.png)                 | ![Bar Chart](chart.png)                                  | ![Bar Chart](chart.png)                       | ![Bar Chart](chart.png)                 | ![Bar Chart](chart.png)                 | ![Bar Chart](chart.png) |

- Low risk of bias
- Unclear risk of bias
- High risk of bias
Summary of risk of bias.

**Figure 3**

Risk of various biases per study.
Figure 4

Forest plot depicting the risk ratio (RR) of microbiological response in patients treated with intravenous colistin-based combination regimen versus colistin alone. (a) overall analysis; (b) subgroup analysis on A. baumannii infections; (c) subgroup analysis on combination regimen for colistin plus rifampicin.
Figure 5

Forest plot depicting the risk ratio (RR) of all-cause mortality in patients treated with intravenous colistin-based combination regimen versus colistin alone. (a) overall analysis; (b) subgroup analysis on A. baumannii infections; (c) subgroup analysis on combination regimen for colistin plus rifampicin.

Figure 6

Forest plot depicting the risk ratio (RR) of infection-related mortality in patients treated with intravenous colistin-based combination regimen versus colistin alone.
Figure 7

Forest plot depicting the risk ratio (RR) of nephrotoxicity in patients treated with intravenous colistin-based combination regimen versus colistin alone.